The healthcare industry is quite inefficient at allocating money to things that are needed and have a decent chance of working.
For example, in the field of oncology there's very little money put into cheap accurate early screening. And an almost obsessive pour of money into trying to understand mid-to-late stage cancers. Even James Watson has criticized this.
It's a sad situation, because we now know early pre-clinical tumours leave a trace of circulating DNA in blood. And it seems like a darn important and doable inference problem to distinguish cancer from control patients.
For example, in the field of oncology there's very little money put into cheap accurate early screening. And an almost obsessive pour of money into trying to understand mid-to-late stage cancers. Even James Watson has criticized this.
It's a sad situation, because we now know early pre-clinical tumours leave a trace of circulating DNA in blood. And it seems like a darn important and doable inference problem to distinguish cancer from control patients.